|
WO2021067347A1
|
|
Dimerizing agent regulated immunoreceptor complexes
|
|
WO2021046500A1
|
|
Transduction efficiency assay
|
|
WO2020252110A1
|
|
Compositions and methods for treating cancer
|
|
WO2020227475A1
|
|
Cll-1 targeted immunotherapies
|
|
WO2020227483A1
|
|
Engineered t cells
|
|
WO2020227474A1
|
|
Cd33 targeted immunotherapies
|
|
WO2020227481A1
|
|
Cd123 targeted immunotherapies
|
|
WO2020219845A1
|
|
Wiskott-aldrich syndrome gene homing endonuclease variants, compositions, and methods of use
|
|
WO2020206061A1
|
|
Manufacturing anti-bcma car t cells
|
|
WO2020198691A1
|
|
β-THALASSEMIA POTENCY ASSAY
|
|
WO2020191358A1
|
|
Adoptive cell therapy
|
|
WO2020191362A1
|
|
Sickle cell potency assay
|
|
WO2020154445A1
|
|
Methods and systems for manufacturing viral vectors
|
|
WO2020123933A1
|
|
Dimerizing agent regulated immunoreceptor complexes
|
|
WO2020123938A1
|
|
Dimerizing agent regulated immunoreceptor complexes
|
|
WO2020123936A1
|
|
Dimerizing agent regulated immunoreceptor complexes
|
|
WO2020123947A1
|
|
Dimerizing agent regulated immunoreceptor complexes
|
|
WO2020123371A2
|
|
Homing endonuclease variants
|
|
WO2020123375A1
|
|
Pdcd-1 homing endonuclease variants
|
|
WO2020097157A2
|
|
Cell therapy vessels
|
